PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment. Recommendations from a joint EPAA - EURL ECVAM ADME workshop.

Regulatory Toxicology and Pharmacology

Volumn 68, Issue 1, 2014, Pages 119-139

  Bessems, Jos G ^a   Loizou, George ^b   Krishnan, Kannan ^c   Clewell, Harvey J ^d   Bernasconi, Camilla ^e   Bois, Frederic ^f   Coecke, Sandra ^e   Collnot, Eva Maria ^g   Diembeck, Walter ^h   Farcal, Lucian Romeo ^e   Geraets, Liesbeth ^a   Gundert Remy, Ursula ⁱ   Kramer, Nynke ^j   Küsters, Gabriele ^k   Leite, Sofia B ^e,l   Pelkonen, Olavi R ^m   Schröder, Klaus ⁿ   Testai, Emanuela ^o   Wilk Zasadna, Iwona ^e   Zaldívar Comenges, José Manuel ^e  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b Mathematical Sciences Unit   (United Kingdom)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^e JOINT RESEARCH CENTRE   (Italy)

^f UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^g SAARLAND UNIVERSITY   (Germany)

^h BEIERSDORF AG   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UTRECHT UNIVERSITY   (Netherlands)

^k European Partnership for Alternative Approaches to Animal Testing   (Belgium)

^l INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^m UNIVERSITY OF OULU   (Finland)

ⁿ BioMed Zet Life Science GmbH   (Austria)

^o ISTITUTO SUPERIORE DI SANITÀ   (Italy)

more..

Author keywords

Development stage; In silico (QSAR) tools; In vitro methods; PBTK; Tier 1 model

Indexed keywords

ABSORPTION; ANIMAL TESTING REDUCTION; ANIMAL TESTING REPLACEMENT; ARTICLE; CHEMICAL INDUSTRY; COMPUTER MODEL; COMPUTER PROGRAM; DATA BASE; DRUG INDUSTRY; EXPERIMENTATION; FOLLOW UP; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REPRODUCIBILITY; RISK ASSESSMENT; TISSUE DISTRIBUTION; TOXICITY TESTING; TOXICOKINETICS; UNCERTAINTY; URINARY EXCRETION; VALIDATION PROCESS; XENOBIOTIC METABOLISM;

AD; APPLICABILITY DOMAIN; DEVELOPMENT STAGE; IN SILICO (QSAR) TOOLS; IN VITRO METHODS; PBTK; PHYSIOLOGICALLY-BASED TOXICOKINETIC; SOLID PHASE MICROEXTRACTION; SPME; TIER 1 MODEL;

ANIMAL TESTING ALTERNATIVES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; RISK ASSESSMENT;

EID: 84890838199     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2013.11.008     Document Type: Article

References (113)

1. Abraham M.H., Kamlet M.J., Taft R.W., et al. Solubility properties in polymers and biological media. 2. The correlation and prediction of the solubilities of nonelectrolytes in biological tissues and fluids. J. Med. Chem. 1985, 28:865-870.
2. Adler S., Basketter D., Creton S., et al. Alternative (non-animal) methods for cosmetics testing: current status and future prospects. Arch. Toxicol. 2011, 85:367-485.
3. Andersen M.E., Green T., Frederick C.B. Physiologically based pharmacokinetic (PBPK) models for nasal tissue dosimetry of organic esters: assessing the state-of-knowledge and risk assessment applications with methyl methacrylate and vinyl acetate. Regul. Toxicol. Pharmacol. 2002, 36:234-245.
4. Austin R.P., Barton P., Cockroft S.L., et al. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Dispos. 2002, 30:1497-1503.
5. Austin R.P., Barton P., Mohmed S., et al. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab. Dispos. 2005, 33:419-425.
6. Barter Z.E., Bayliss M.K., Beaune P.H. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 2007, 8:33-45.
7. Béliveau M., Tardif R., Krishnan K. Quantitative structure-property relationships for physiologically based pharmacokinetic modeling of volatile organic chemicals in rats. Toxicol. Appl. Pharmacol. 2003, 189:221-232.
8. Béliveau M., Lipscomb J., Tardif R., et al. Quantitative structure-property relationships for interspecies extrapolation of the inhalation pharmacokinetics of organic chemicals. Chem. Res. Toxicol. 2005, 18:475-485.
9. Bessems, J., 2009. Opinion on the usefulness of in vitro data for human risk assessment Suggestions for better use of non-testing approaches. Letter Report 320016002/2009RIVM. Bilthoven, The Netherlands.
10. Bonn B., Leandersson C., Fontaine F., et al. Enhanced metabolite identification with MSE and a semiautomated software for structural elucidation. Rapid Commun. Mass Spectrom. 2010, 24:3127-3138.
11. Bouwman T., Cronin M.T., Bessems J.G., et al. Improving the applicability of (Q)SARs for percutaneous penetration in regulatory risk assessment. Hum. Exp. Toxicol. 2008, 27:269-276.
12. Brightman F.A., Leahy D.E., Searle G.E., et al. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metab. Dispos. 2006, 34:94-101.
13. Brightman F.A., Leahy D.E., Searle G.E., et al. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma. Drug Metab. Dispos. 2006, 34:84-93.
14. Brown R.P., Delp M.D., Lindstedt S.L., et al. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 1997, 13:407-484.
15. Buist H.E., De Wit-Bos L., Bouwman T., et al. Predicting blood:air partition coefficients using basic physicochemical properties. Regul. Toxicol. Pharmacol. 2012, 62:23-28.
16. Caldwell J.C., Evans M.V., Krishnan K. Cutting edge PBPK models and analyses: providing the basis for future modeling efforts and bridges to emerging toxicology paradigms. J. Toxicol. 2012, 2012(2012):852384. 10.1155/2012/852384.
17. Campbell Jr., J.L., Clewell, R.A., Gentry, P.R., et al., 2012. Physiologically based pharmacokinetic/toxicokinetic modeling. In: Reisfeld, B., Mayeno, A.N. (Eds.), Computational Toxicology: Volume I. In: Walker, J.M. (Series Ed.), Methods in Molecular Biology, vol. 929. Humana Press, pp. 439-499.
18. Chiu W.A., Barton H.A., DeWoskin R.S., et al. Evaluation of physiologically based pharmacokinetic models for use in risk assessment. J. Appl. Toxicol. 2007, 27:218-237.
19. Clewell R.A., Clewell H.J. Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul. Toxicol. Pharmacol. 2008, 50:129-143.
20. Coecke S., Ahr H., Blaauboer B.J., et al. Metabolism: a bottleneck in in vitro toxicological test development. Altern. Lab. Anim. 2006, 34:49-84.
21. Coecke S., Pelkonen O., Batista Leite S. Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. Toxicol. In Vitro 2012, 4.
22. Cruciani G. Metabolites: structure determination and prediction. Drug Discov. Today Technol. 2013, 10(1):e145-e146.
23. De Buck S.S., Sinha V.K., Fenu L.A., et al. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab. Dispos. 2007, 35:1766-1780.
24. De Groot M.J., Ekins S. Pharmacophore modeling of cytochromes P450. Adv. Drug Deliv. 2002, 54:367-383.
25. DeJongh J., Verhaar H.J., Hermens J.L. A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch. Toxicol. 1997, 72:17-25.
26. Dressman J.B., Thelen K., Jantratid E. Towards quantitative prediction of oral drug absorption. Clin. Pharmacokinet. 2008, 47:655-667.
27. EC, 2009. EC Regulation 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. Official Journal of the European Communities L 342, 30.11.2009. pp. 59-209.
28. EC, 2013a. Communication from the Commission to the European Parliament and the Council on the animal testing and marketing ban and on the state of play in relation to alternative methods in the field of cosmetics. COM(2013) 135 Final, 11.3.2013. Brussels, Belgium.
29. EC, 2013b. SCHER (Scientific Committee on Health and Environmental Risks), SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks), SCCS (Scientific Committee on Consumer Safety). Addressing the New Challenges for Risk Assessment, March 2013. http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_131.pdf.
30. ECHA, 2012. Guidance for the implementation of REACH. Guidance on information requirements and chemical safety assessment. Chapter R.7.12 Guidance on Toxicokinetics. European Chemicals Agency ECHA, Helsinki, Finland.
31. Ekins S., Obach R.S. Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance. Am. Soc. Pharmacol. Exp. Ther. 2000, 295:463-473.
32. EPAA (European Partnership for Alternative Approaches to Animal Testing), 2011. EPAA - ECVAM Joint ADME Workshop "Potential for Further Integration of Toxicokinetic Modelling into the Prediction of In Vivo Dose-response Curves Without Animal Experiments". Flash Report. <>. http://ec.europa.eu/enterprise/epaa/2_activities/2_3_comm_and_dissem/adme-flash-report.pdf.
33. Germani M., Crivori P., Rocchetti M., et al. Evaluation of a physiologically-based pharmacokinetic approach for simulating the first-time-in-animal study. Basic Clin. Pharmacol. Toxicol. 2005, 96:254-256.
34. Gueorguieva I., Nestorov I.A., Murby S., et al. Development of a whole body physiologically based model to characterise the pharmacokinetics of benzodiazepines. 1: estimation of rat tissue-plasma partition ratios. J. Pharmacokinet. Pharmacodyn. 2004, 31:269-298.
35. Haddad S., Poulin P., Krishnan K. Relative lipid content as the sole mechanistic determinant of the adipose tissue:blood partition coefficients of highly lipophilic organic chemicals. Chemosphere 2000, 40:839-843.
36. Hartung T., Bremer S., Casati S., et al. A modular approach to the ECVAM principles on test validity. Altern. Lab. Anim. 2004, 32:467-472.
37. Hewitt N.J., Edwards R.J., Fritsche E., Goebel C., Aeby P., Scheel J., Reisinger K., Ouédraogo G., Duche D., Eilstein J., Latil A., Kenny J., Moore C., Kuehnl J., Barroso J., Fautz R., Pfuhler S. Use of human in vitro skin models for accurate and ethical risk assessment: metabolic considerations. Toxicol. Sci. 2013, 133(2):209-217.
38. Hou T., Wang J. Structure-ADME relationship: still a long way to go. Expert. Opin. Drug Metab. Toxicol. 2008, 4:759-770.
39. Hubatsch I., Ragnarsson E.G.E., Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2007, 2:2111-2119.
40. ICRP, 2002. Basic Anatomical and physiological data for use in radiological protection reference values. ICRP Publication 89. Ann. ICRP 32. pp. 3-4. http://www.icrp.org/publication.asp?id=ICRP%20Publication%2089.
41. Jakubowski M., Czerczak S. Calculating the retention of volatile organic compounds in the lung on the basis of their physicochemical properties. Environ. Toxicol. Pharmacol. 2009, 28:311-315.
42. Jones H.M., et al. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 2006, 45:511-542.
43. Kamgang E., Peyret T., Krishnan K. An integrated QSPR-PBPK modelling approach for in vitro-in vivo extrapolation of pharmacokinetics in rats. SAR QSAR Environ. Res. 2008, 19:669-680.
44. Kenyon, E.M., 2012. Interspecies extrapolation. In: Reisfeld, B., Mayeno, A.N. (Eds.), Computational Toxicology: Volume I. In: Walker, J.M. (Series Ed.), Methods in Molecular Biology, vol. 929. Humana Press, pp. 501-520.
45. Kirchmair J., Williamson M.J., Tyzack J.D., et al. Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms. J. Chem. Inf. Model. 2012, 52:617-648.
46. Langowski J., Long A. Computer systems for the prediction of xenobiotic metabolism. Adv. Drug Deliv. Rev. 2002, 54:407-415.
47. Lewis D.F.V. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Towards the prediction of human P450 substrate specificity and metabolism. Biochem. Pharmacol. 2000, 60:293-306.
48. Lian G., Chen L., Han L. An evaluation of mathematical models for predicting skin permeability. J. Pharm. Sci. 2008, 97:584-598.
49. Lipinski C.A., Lombardo F., Dominy B.W., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
50. Lipscomb J.C., Haddad S., Poet T., et al. Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment. Adv. Exp. Med. Biol. 2012, 745:76-95.
51. Loizou G.D., Spendiff M., Barton H.A., et al. Development of good modelling practice for physiologically based oharmacokinetic models for use in risk assessment: the first steps. Regul. Toxicol. Pharmacol. 2008, 50:400-411.
52. Louisse J., de Jong E., van de Sandt J.J., et al. The use of in vitro toxicity data and physiologically based kinetic modelling to predict dose-response curves for in vivo developmental toxicity of glycol ethers in rat and man. Toxicol. Sci. 2010, 118:470-484.
53. Madden J.C., Cronin M.T. Structure-based methods for the prediction of drug metabolism. Expert. Opin. Drug. Metab. Toxicol. 2006, 2:545-557.
54. Manga N., Duffy J.C., Rowe P.H., et al. A hierarchical QSAR model for urinary excretion of drugs in humans as a predictive tool for biotransformation. QSAR Comb. Sci. 2003, 22:263-273.
55. Mayer J., Van de Waterbeemd H. Development of quantitative structure-pharmacokinetic relationships. Environ. Health Perspect. 1985, 61:295-306.
56. McNally K., et al. A workflow for global sensitivity analysis of PBTK models. Front. Pharmacol. Predictive Toxic. 2011, 2:1-21.
57. McNally K., et al. Reconstruction of exposure to m-xylene from human biomonitoring data using PBTK modelling, Bayesian inference, and Markov Chain Monte Carlo Simulation. J. Toxicol. 2012, 2012(2012). Article ID 760281, 18 pages. 10.1155/2012/760281.
58. Meulenberg C.J., Vijverberg H.P. Empirical relations predicting human and rat tissue:air partition coefficients of volatile organic compounds. Toxicol. Appl. Pharmacol. 2000, 165:206-216.
59. Meulenberg C.J., Wijnkerm A.G., Vijverberg H.P. Relationship between olive oil:air, saline:air, and rat brain:air partition coefficients of organic solvents in vitro. J. Toxicol. Environ. Health 2003, 66:1985-1998.
60. Mielke H., Gundert-Remy U. Physiologically based toxicokinetic modelling as a tool to support risk assessment: three case studies. J. Toxicol. 2012, 2012. Article ID 359471, 11 pages. 10.1155/2012/359471.
61. Moss G.P., Dearden J.C., Patel H., Cronin M.T.D. Quantitative structure-permeability relationships (QSPRs) for percutaneous absorption. Toxicol. In Vitro 2002, 16:299-317.
62. NRC, 2007. Toxicity Testing in the 21st Century: A Vision and A Strategy. Committee on Toxicity Testing and Assessment of Environmental Agents, National Research Council. National Academy Press, Washington, DC.
63. OECD, 2004a. Oecd guidelines for the testing of chemicals/section 4: health effects. Skin absorption. In Vitro Method. No. 428. OECD, Paris.
64. OECD, 2004b. OECD guideline for the testing of chemicals. In Vitro Skin Corrosion: Transcutaneous Electrical Resistance Test (TER). No. 430. OECD, Paris.
65. OECD, 2004c. OECD guideline for the testing of chemicals. In Vitro Skin Corrosion: Reconstructed Human Epidermis (RhE) Test Method. No. 431. OECD, Paris.
66. OECD, 2004d. OECD Guideline for the testing of chemicals. In Vitro 3T3 NRU Phototoxicity Test. No. 432. OECD, Paris.
67. OECD, 2005. OECD Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment. No. 34. OECD, Paris.
68. OECD, 2009a. OECD guideline for the testing of chemicals. Bovine Corneal Opacity and Permeability Test Method for Identifying Ocular Corrosives and Severe Irritants. No. 437. OECD, Paris.
69. OECD, 2009b. OECD guideline for the testing of chemicals. Isolated Chicken Eye Test Method for Identifying Ocular Corrosives and Severe Irritants. No. 438. OECD, Paris.
70. OECD, 2010a. OECD guideline for the testing of chemicals. Toxicokinetics. No. 417. OECD, Paris.
71. OECD, 2010b. OECD guideline for the testing of chemicals. In Vitro Skin Irritation - Reconstructed Human Epidermis Test Method. No. 439. OECD, Paris.
72. Parham F.M., Kohn M.C., Matthews H.B., et al. Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls: I. Tissue:blood partition coefficients. Toxicol. Appl. Pharmacol. 1997, 144:340-347.
73. Parham F.M., Portier C.J. Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. II. Rates of metabolism. Toxicol. Appl. Pharmacol. 1998, 151:110-116.
74. Pelkonen O., Tolonen A., Korjamo T., et al. From known knowns to known unknowns: predicting in vivo drug metabolites. Bioanalysis 2009, 1:393-414.
75. Péry A.R.R., Brochot C., Zeman F.A., Mombelli E., Desmots S., Pavan M., Fioravanzo E., Zaldívar J.-M. Prediction of dose-hepatotoxic response in humans based on toxicokinetic/toxicodynamic modeling with or without in vivo data: a case study with acetaminophen. Toxicol. Lett. 2013, 220(2013):26-34.
76. Peters S.A. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin. Pharmacokinet. 2008, 47:261-275.
77. Peyret T., Poulin P., Krishnan K. A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. Toxicol. Appl. Pharmacol. 2010, 249:197-207.
78. Peyret T., Krishnan K. QSARs for PBPK modelling of environmental contaminants. SAR QSAR Environ. Res. 2011, 22:129-169.
79. Polak S., Ghobadi C., Mishra H., et al. Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorption. J. Pharm. Sci. 2012, 101:2584-2595.
80. Poulin, P., Haddad, S., 2013. Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data. J. Pharm. Sci. doi:10.1002/jps.23502.
81. Poulin P., Krishnan K. A biologically-based algorithm for predicting human tissue: blood partition coefficients of organic chemicals. Hum. Exp. Toxicol. 1995, 14:273-280.
82. Poulin P., Krishnan K. A tissue composition-based algorithm for predicting tissue:air partition coefficients of organic chemicals. Toxicol. Appl. Pharmacol. 1996, 136:126-130.
83. Poulin P., Krishnan K. A mechanistic algorithm for predicting blood:air partition coefficients of organic chemicals with the consideration of reversible binding in hemoglobin. Toxicol. Appl. Pharmacol. 1996, 136:131-137.
84. Poulin P., Krishnan K. Molecular structure based prediction of partition coefficients of organic chemicals for physiological pharmacokinetic models. Toxicol. Methods 1996, 6:117-137.
85. Poulin P., Krishnan K. Molecular structure-based prediction of the toxicokinetics of inhaled vapors in humans. Int. J. Toxicol. 1999, 18:7-18.
86. Poulin P., Theil F.P. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J. Pharm. Sci. 2000, 89:16-35.
87. Poulin P., Theil F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 2002, 91:129-156.
88. Poulin P., Theil F.P. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci 2002, 91:1358-1370.
89. Price K., Krishnan K. An integrated QSAR-PBPK modelling approach for predicting the inhalation toxicokinetics of mixtures of volatile organic chemicals in the rat. SAR QSAR Environ. Res. 2011, 22:107-128.
90. Rietjens I.M., Louisse J., Punt A. Tutorial on physiologically based kinetic modelling in molecular nutrition and food research. Mol. Nutr. Food Res. 2011, 55:941-956.
91. Rodgers T., Leahy D., Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci. 2005, 94:1259-1276.
92. Rodgers T., Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 2006, 95:1238-1257.
93. Rodgers T., Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm. Res. 2007, 24:918-933.
94. Rostami A.A. Computational modeling of aerosol deposition in respiratory tract: a review. Inhal. Toxicol. 2009, 2:262-290.
95. Rotroff D.M., Wetmore B.A., Dix D.J., et al. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol. Sci. 2010, 117:348-358.
96. Rousu T., Hokkanen J., Pelkonen O.R., et al. Applicability of generic assays based on liquid chromatography-electrospray mass spectrometry to study in vitro metabolism of 55 structurally diverse compounds. Front. Pharmacol. 2010, 1:10.
97. Rowland M., Tozer T.N. Clinical Pharmacokinetics - Concepts and Applications 1995, Williams and Wilkins, Baltimore. third ed.
98. Rydberg P., Vasanthanathan P., Oostenbrink C., et al. Fast prediction of cytochrome P450 mediated drug metabolism. Chem. Med. Chem. 2009, 4:2070-2079.
99. Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicol. In Vitro 2008, 22:457-467.
100. Schroeder K., Bremm K.D., Alepee N., et al. Report from the EPAA workshop: in vitro ADME in safety testing used by EPAA industry sectors. Toxicol. In Vitro 2011, 25:589-604.
101. Seydel J.K., Schaper K.J. Quantitative structure-pharmacokinetic relationships and drug design. Pharm. Ther. 1982, 15:131-182.
102. Sinkó B., Garrirues T.M., Balogh Gy.T. Skin-PAMPA: a new method for fast prediction of skinpenetration. Eur. J. Pharm. Sci. 2012, 45:698-707.
103. Sun H., Scott D.O. Structure-based drug metabolism predictions for drug design. Chem. Biol. Drug. Des. 2012, 74:3-17.
104. Theil F.P., Guentert T.W., Haddad S., et al. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol. Lett. 2003, 138:29-49.
105. Valcke M., Krishnan K. An assessment of the impact of physico-chemical and biochemical characteristics on the human kinetic adjustment factor for systemic toxicants. Toxicology 2011, 286:36-47.
106. Van Eijl S., Zhu Z., Cupitt J., Gierula M., Götz C., Fritsche E., Edwards R.J. Elucidation of xenobiotic metabolism pathways in human skin and human skin models by proteomic profiling. PLoS One 2012, 7(7):e41721.
107. Wetmore B.A., Wambaugh J.F., Ferguson S.S., et al. Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol. Sci. 2012, 125:157-174.
108. Wetmore B.A., Wambaugh J.F., Ferguson S.S., et al. The relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode-of-action from high-throughput in vitro toxicity assays. Toxicol. Sci. 2013, 132:327-346.
109. Waller C.L., Evans M.V., McKinney J.D. Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. Am. Soc. Pharmacol. Exp. Ther. 1996, 24:203-210.
110. WHO, 2010. Characterization and Application of Physiologically Based Pharmacokinetic Models in Risk Assessment: Harmonization Project Document No.9. WHO, Geneva. <>. http://www.who.int/ipcs/methods/harmonization/areas/pbpk/en/.
111. Yoon M., Campbell J.L., Andersen M.E. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit. Rev. Toxicol. 2012, 42:633-652.
112. Zamora I., Fontaine F., Serra B., et al. High-throughput, computer assisted, specific MetID. a revolution for drug discovery. Drug Discov. Today Technol. 2013, 10(1):e199-e205.
113. Zorin S., Kuylenstierna F., Thulin H. In vitro test of nicotine's permeability through human skin. Risk evaluation and safety aspects. Ann. Occup. Hyg. 1999, 43:405-413.